Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Disitamab Vedotin”

100 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 100 results

Not applicableNot Yet RecruitingNCT07504939
What this trial is testing

Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma

Who this might be right for
Upper Tract Urothelial Carcinoma Receiving Kidney-sparing TherapyUpper Tract Urothelial Carcinoma
Peking University First Hospital 36
Large-scale testing (Phase 3)Looking for participantsNCT07693959
What this trial is testing

Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC

Who this might be right for
MIBC
Zhiquan Hu 170
Large-scale testing (Phase 3)Looking for participantsNCT06278870
What this trial is testing

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Who this might be right for
HER2-positive Metastatic Breast CancerFirst-line Treatment
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 312
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07509424
What this trial is testing

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Who this might be right for
Rectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 29
Testing effectiveness (Phase 2)Looking for participantsNCT06210490
What this trial is testing

A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery

Who this might be right for
Upper Urinary Tract Urothelial Carcinoma
Peking University First Hospital 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06187506
What this trial is testing

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder CancerHER-2 Protein Overexpression
Fudan University 20
Large-scale testing (Phase 3)Not Yet RecruitingNCT06944496
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Carcinoma
RemeGen Co., Ltd. 616
Testing effectiveness (Phase 2)UnknownNCT05912205
What this trial is testing

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

Who this might be right for
Urothelial Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 30
Not applicableUnknownNCT06857747
What this trial is testing

Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.

Who this might be right for
Breast Cancer
QIAO LI 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07498907
What this trial is testing

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

Who this might be right for
Upper Tract Urothelial Carcinoma
Peking University First Hospital 192
Large-scale testing (Phase 3)Looking for participantsNCT06221748
What this trial is testing

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd. 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06385873
What this trial is testing

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Who this might be right for
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 32
Large-scale testing (Phase 3)Looking for participantsNCT05904964
What this trial is testing

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Who this might be right for
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 288
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07142200
What this trial is testing

A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer
RenJi Hospital 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06630871
What this trial is testing

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

Who this might be right for
NMIBC
Fujian Medical University Union Hospital 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06185400
What this trial is testing

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Who this might be right for
Non Small Cell Lung CancerERBB2 Mutation-Related TumorsERBB2 Gene Duplication+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 108
Testing effectiveness (Phase 2)Looking for participantsNCT07646145
What this trial is testing

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shanxi Province Cancer Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT05912816
What this trial is testing

Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Who this might be right for
Upper Urinary Tract Urothelial CarcinomaKidney PreservationHER-2 ADC+1 more
RenJi Hospital 20
Testing effectiveness (Phase 2)UnknownNCT06233864
What this trial is testing

The Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Sun Yat-sen University 63
Testing effectiveness (Phase 2)UnknownNCT05313906
What this trial is testing

RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer

Who this might be right for
Advanced Gastric CarcinomaHER2-positive Gastric Cancer
Henan Cancer Hospital 40
Next Page